⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for alk+

Every month we try and update this database with for alk+ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Expanded Access to Ensartinib for Participants With ALK+ NSCLCNCT04146571
Non-Small Cell ...
ALK Gene Rearra...
Ensartinib
18 Years - Xcovery Holdings, Inc.
Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)NCT02299505
Non-Small Cell ...
ceritinib
18 Years - Novartis
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibNCT05948462
Lung Cancer
Non-small Cell ...
Lorlatinib
Cisplatin or Ca...
Pemetrexed
18 Years - SCRI Development Innovations, LLC
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsNCT04644315
Neoplasms
Colorectal Neop...
Melanoma
Pancreatic Neop...
Sarcoma
Ovarian Neoplas...
Brain Neoplasms
Thyroid Neoplas...
Neuroendocrine ...
Cholangiocarcin...
Salivary Gland ...
Head and Neck N...
Thyroid Cancer,...
Lymphoma, Large...
Neoplasms by Si...
Respiratory Tra...
Thoracic Neopla...
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Intestinal Neop...
Gastrointestina...
Digestive Syste...
Digestive Syste...
Gastrointestina...
Colonic Disease...
Intestinal Dise...
Central Nervous...
Alectinib
18 Years - Hoffmann-La Roche
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsNCT04644315
Neoplasms
Colorectal Neop...
Melanoma
Pancreatic Neop...
Sarcoma
Ovarian Neoplas...
Brain Neoplasms
Thyroid Neoplas...
Neuroendocrine ...
Cholangiocarcin...
Salivary Gland ...
Head and Neck N...
Thyroid Cancer,...
Lymphoma, Large...
Neoplasms by Si...
Respiratory Tra...
Thoracic Neopla...
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Intestinal Neop...
Gastrointestina...
Digestive Syste...
Digestive Syste...
Gastrointestina...
Colonic Disease...
Intestinal Dise...
Central Nervous...
Alectinib
18 Years - Hoffmann-La Roche
A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and LymphomasNCT02048488
Solid Tumors
Lymphomas
TSR-011
18 Years - Tesaro, Inc.
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibNCT05948462
Lung Cancer
Non-small Cell ...
Lorlatinib
Cisplatin or Ca...
Pemetrexed
18 Years - SCRI Development Innovations, LLC
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: